Stock Earnings

Question 1

What are Shenzhen Hepalink Pharmaceutical Group Co Ltd's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Shenzhen Hepalink Pharmaceutical Group Co Ltd has a total asset of $17,343, Net profit of $646

Question 2

What are the key financial ratios for SHEZF?

Accepted Answer

Shenzhen Hepalink Pharmaceutical Group Co Ltd's Current ratio is 3.33, has a Net margin is 12.23, sales per share of $3.59.

Question 3

How is Shenzhen Hepalink Pharmaceutical Group Co Ltd's revenue broken down by segment or geography?

Accepted Answer

Shenzhen Hepalink Pharmaceutical Group Co Ltd largest revenue segment is Preparation, at a revenue of 2,986,074,622 in the most earnings release.For geography, Europe is the primary market for Shenzhen Hepalink Pharmaceutical Group Co Ltd, at a revenue of 2,372,845,163.

Question 4

Is Shenzhen Hepalink Pharmaceutical Group Co Ltd profitable?

Accepted Answer

yes, according to the latest financial statements, Shenzhen Hepalink Pharmaceutical Group Co Ltd has a net profit of $646

Question 5

Does Shenzhen Hepalink Pharmaceutical Group Co Ltd have any liabilities?

Accepted Answer

yes, Shenzhen Hepalink Pharmaceutical Group Co Ltd has liability of 5,194

Question 6

How many outstanding shares for Shenzhen Hepalink Pharmaceutical Group Co Ltd?

Accepted Answer

Shenzhen Hepalink Pharmaceutical Group Co Ltd has a total outstanding shares of 1,467.29

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	5,260	5,280	5,445	7,159	6,365	5,332
Revenue Growth (YoY)	-6%	-3%	-24%	12%	19%	15%
Cost of Revenue	3,655	3,532	4,501	4,863	4,367	3,300
Gross Profit	1,605	1,748	944	2,295	1,998	2,031
Selling, General & Admin	855	781	930	972	878	767
Research & Development	233	203	173	244	216	154
Operating Expenses	1,297	1,099	1,232	1,292	1,186	996
Other Non Operating Income (Expenses)	0	-14	-66	1	-4	-1
Pretax Income	442	726	-928	829	222	1,327
Income Tax Expense	58	101	-126	114	-11	306
Net Income	404	646	-783	727	240	1,024
Net Income Growth	-267%	-183%	-208%	202.99%	-77%	-3%
Shares Outstanding (Diluted)	1,467.29	1,467.29	1,467.29	1,467.29	1,467.29	1,467.3
Shares Change (YoY)	0%	0%	0%	0%	0%	18%
EPS (Diluted)	0.27	0.44	-0.53	0.49	0.16	0.7
EPS Growth	-267%	-183%	-208%	202%	-77%	-18%
Free Cash Flow	1,751	1,991	-46	-979	-200	-175
Free Cash Flow Per Share	1.19	1.35	-0.03	-0.66	-0.13	-0.11
Gross Margin	30.51%	33.1%	17.33%	32.05%	31.39%	38.09%
Operating Margin	5.85%	12.27%	-5.28%	14.01%	12.74%	19.41%
Profit Margin	7.68%	12.23%	-14.38%	10.15%	3.77%	19.2%
Free Cash Flow Margin	33.28%	37.7%	-0.84%	-13.67%	-3.14%	-3.28%
EBITDA	--	744	-188	1,095	911	1,136
EBITDA Margin	--	14.09%	-3.45%	15.29%	14.31%	21.3%
D&A For EBITDA	--	96	100	92	100	101
EBIT	308	648	-288	1,003	811	1,035
EBIT Margin	5.85%	12.27%	-5.28%	14.01%	12.74%	19.41%
Effective Tax Rate	13.12%	13.91%	13.57%	13.75%	-4.95%	23.05%

Shenzhen Hepalink Pharmaceutical Group Co Ltd (SHEZF) Price

SHEZF Stock Price Chart

SHEZF Income

Follow-Up Questions